Diversified Trust Co Acquires 10,066 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Diversified Trust Co lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 57.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 27,702 shares of the company’s stock after acquiring an additional 10,066 shares during the quarter. Diversified Trust Co’s holdings in BridgeBio Pharma were worth $857,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Parkman Healthcare Partners LLC raised its holdings in BridgeBio Pharma by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 100,734 shares of the company’s stock valued at $4,067,000 after buying an additional 734 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in BridgeBio Pharma by 1.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 65,773 shares of the company’s stock valued at $2,655,000 after buying an additional 904 shares during the last quarter. Assetmark Inc. raised its holdings in BridgeBio Pharma by 46.8% during the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock valued at $118,000 after buying an additional 935 shares during the last quarter. Quarry LP bought a new stake in BridgeBio Pharma during the 4th quarter valued at $50,000. Finally, Handelsbanken Fonder AB raised its holdings in BridgeBio Pharma by 6.5% during the 4th quarter. Handelsbanken Fonder AB now owns 26,350 shares of the company’s stock valued at $1,064,000 after buying an additional 1,600 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Randal W. Scott sold 1,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $28.84, for a total transaction of $28,840.00. Following the sale, the director now owns 5,500 shares of the company’s stock, valued at approximately $158,620. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 24.66% of the company’s stock.

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $24.91 on Wednesday. BridgeBio Pharma, Inc. has a one year low of $16.61 and a one year high of $44.32. The company’s 50-day moving average is $27.38 and its 200 day moving average is $31.48. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -7.74 and a beta of 1.06.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.35. The firm had revenue of $211.12 million for the quarter, compared to analysts’ expectations of $140.06 million. As a group, research analysts predict that BridgeBio Pharma, Inc. will post -3.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BBIO. Raymond James began coverage on shares of BridgeBio Pharma in a report on Thursday, March 21st. They set an “outperform” rating and a $45.00 price target for the company. UBS Group decreased their price objective on shares of BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. Mizuho decreased their price objective on shares of BridgeBio Pharma from $60.00 to $53.00 and set a “buy” rating for the company in a report on Tuesday, March 5th. HC Wainwright restated a “buy” rating and issued a $43.00 price objective on shares of BridgeBio Pharma in a report on Thursday, June 20th. Finally, JPMorgan Chase & Co. upped their price objective on shares of BridgeBio Pharma from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.21.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.